Phase 2 Study of ONC201 in Neuroendocrine Tumors

Trial Profile

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Phase of Trial: Phase II

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs ONC 201 (Primary)
  • Indications Neuroendocrine tumours; Phaeochromocytoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Jan 2019.
    • 09 Aug 2017 According to an Oncoceutics media release,the first patient has been treated in this trial at the Cleveland Clinic.
    • 26 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top